Alyeska Investment Group
STLN

Alyeska Investment Group’s Starling Oncology Institute, Inc. Common Stock STLN Stock Holding History

Alyeska Investment Group’s Portfolio STLN Stock Details STLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-83,862
Closed -$293K – 727
2025
Q3 		$293K Buy
+83,862
New +$287K ﹤0.01% 569
2024
Q3 		– Sell
-83,862
Closed -$38.6K – 686
2024
Q2 		$38.6K Buy
+83,862
New +$71.6K ﹤0.01% 550
2024
Q1 		– Sell
-83,862
Closed -$171K – 619
2023
Q4 		$171K Buy
+83,862
New +$145K ﹤0.01% 481

Other funds holding STLN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
CP
CenterBook Partners Greenwich, Connecticut $1.86B AUM 24.52% 1-Year Est. Return
KWM
Kanen Wealth Management Coconut Creek, Florida $278M AUM 38.85% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
JAIC
Josh Arnold Investment Consultant Edina, Minnesota $117M AUM 26.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
WC
Wexford Capital West Palm Beach, Florida $690M AUM 57.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Alyeska Investment Group's STLN Position: Q4 2021 in Review

Alyeska Investment Group sold out of Starling Oncology Institute, Inc. Common Stock (STLN) in Q4 2021, closing a stake of 235,448 shares — an estimated $2.34M sold.

Alyeska Investment Group first reported a position in STLN in Q3 2020 and held it in 5 quarters. The position peaked at $2.54M in Q4 2020. 21 funds tracked by Wall St. Rank hold STLN as of Q4 2021.

  • Alyeska Investment Group reported no remaining Starling Oncology Institute, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • Alyeska Investment Group sold 235,448 Starling Oncology Institute, Inc. Common Stock shares in Q4 2021, an estimated $2.34M.
  • Alyeska Investment Group first reported a position in Starling Oncology Institute, Inc. Common Stock in Q3 2020 and held it in 5 quarters.
  • Alyeska Investment Group's Starling Oncology Institute, Inc. Common Stock position peaked at $2.54M in Q4 2020.
  • 21 funds tracked by Wall St. Rank held Starling Oncology Institute, Inc. Common Stock as of Q4 2021.

Based on Alyeska Investment Group's 13F filing for Q4 2021, filed 14 Feb 2022.